Core Viewpoint - The company has received a registration certificate for a special medical purpose formula food, which is expected to enhance its product portfolio and market competitiveness [1][4]. Group 1: Registration Certificate Details - The product is named "Xiao Wei Yuan Su" and is classified as a special medical purpose full-nutrition formula food [1]. - The registration number is 国食注字TY20250052, and it is valid until October 26, 2030 [1]. - The product is designed for children aged 1 to 10 with dietary restrictions, digestive absorption issues, or metabolic disorders [1]. - The product comes in various specifications, including 60g, 90g, 150g, 200g, and 400g [1]. - The product has a shelf life of 24 months [1]. Group 2: Market Insights - The special medical food market in China is projected to exceed 16 billion RMB in 2024, accounting for 9.15% of the global market [2]. - There are currently 279 approved special medical food registration certificates in China, with only 21 for full-nutrition formula foods suitable for the 1-10 age group [2]. Group 3: R&D Investment - The company has invested approximately 4.0742 million RMB in the research and development of this product [3].

Core Viewpoint - Recently, the company received the Special Medical Purpose Formula Food Registration Certificate approved by the National Market Supervision Administration [2] Group 1 - The company announced the receipt of the registration certificate on the evening of November 12 [2]

证券代码：600351 证券简称：亚宝药业 公告编号：2025-043 亚宝药业集团股份有限公司 关于取得特殊医学用途配方食品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，亚宝药业集团股份有限公司（以下简称"公司"）收到了国家市场监 督管理总局核准签发的《特殊医学用途配方食品注册证书》。现将相关情况公告 如下： 一、注册证书主要内容 8、适用人群：1～10 岁进食受限、消化吸收障碍、代谢紊乱等需要补充营 养的人群。 9、净含量和规格：60g（10g×6），90g（10g×9），150g（10g×15），200g（10g×20）， 400g（10g×40） 10、保质期：24 个月 11、审批结论：经审核，该产品符合《中华人民共和国食品安全法》《特殊 医学用途配方食品注册管理办法》及有关规定，现予批准注册。 1、通用名称：特殊医学用途全营养配方食品 2、商品名称：小唯源素® 3、企业名称：亚宝药业集团股份有限公司 4、生产地址：山西省运城市芮城县富民路 43 号 5、注册号：国食注字 TY20250052 ...

Core Viewpoint - The announcement details the stock pledge and repurchase activities of Yabao Pharmaceutical Group Co., Ltd, highlighting the significant shareholding and the ongoing share repurchase program [2][5]. Group 1: Stock Pledge Information - As of the announcement date, the controlling shareholder, Shanxi Yabao Investment Group Co., Ltd, holds 94,300,000 shares, accounting for 13.47% of the total share capital [2]. - A total of 26,850,000 shares have been pledged, representing 28.47% of the shares held by the controlling shareholder and 3.84% of the company's total share capital [2]. - The pledged shares are not used as collateral for major asset restructuring or other guarantees [2]. Group 2: Share Repurchase Program - The company approved a share repurchase plan on May 16, 2025, with a total fund amount between RMB 50 million and RMB 100 million, and a maximum repurchase price of RMB 6.95 per share [7]. - As of October 31, 2025, the company has repurchased 8,000,000 shares, which is 1.14% of the total share capital, with a total expenditure of RMB 52,151,912.00 [8]. - The highest and lowest transaction prices during the repurchase were RMB 6.65 and RMB 6.30 per share, respectively [8].

证券日报网讯11月3日晚间，亚宝药业（600351）发布公告称，截至2025年10月31日，公司通过集中竞 价交易方式已累计回购股份8，000，000股，占公司总股本的比例为1.14%。 ...

Core Viewpoint - Yabao Pharmaceutical (SH 600351) announced that its controlling shareholder, Shanxi Yabao Investment Group, holds 94.3 million shares, accounting for 13.47% of the total share capital, with 26.85 million shares pledged, representing 28.47% of its holdings and 3.84% of the total share capital [1] Financial Performance - For the fiscal year 2024, Yabao Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 75.46%, pharmaceutical wholesale for 21.37%, other trading for 1.88%, and other businesses for 1.29% [1] - As of the announcement date, Yabao Pharmaceutical has a market capitalization of 4.8 billion yuan [1]

Core Viewpoint - The company, Yabao Pharmaceutical (600351.SH), has successfully repurchased a total of 8 million shares, representing 1.14% of its total share capital, as part of its share repurchase plan [1] Summary by Relevant Sections - **Share Repurchase Details** - The repurchase was conducted through centralized bidding transactions [1] - The highest transaction price was 6.65 CNY per share, while the lowest was 6.30 CNY per share [1] - The total amount paid for the repurchased shares was 52.1519 million CNY, excluding transaction fees [1] - **Compliance and Regulations** - The share repurchase has been carried out in accordance with relevant laws and regulations, as well as the company's share repurchase plan requirements [1]

证券代码：600351 证券简称：亚宝药业 公告编号：2025-042 亚宝药业集团股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/26，由董事会提议 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 5 11 | 16 | 日~2025 | 年 | 月 | 14 | 日 | | 预计回购金额 | 0.5亿元~1亿元 | | | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 8,000,000股 | | | | | | | | 累计已回购股数占总股本比例 | 1.14% | | | | | | | | 累计已回购金额 | 52 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●截至本公告日，亚宝药业集团股份有限公司（以下简称"公司"）控股股 东山西亚宝投资集团有限公司（以下简称"亚宝投资"）持有本公司股份94,300,000 股，占公司总股本的13.47%；亚宝投资所持有的公司股份累计质押股份数为 26,850,000股，占其持有公司股份总数的28.47%，占公司总股本的3.84%。 公司于2025年11月2日接到控股股东亚宝投资关于进行股票质押式回购交易 的通知，现将相关情况公告如下： 证券代码：600351 证券简称：亚宝药业 公告编号：2025-041 亚宝药业集团股份有限公司 关于控股股东进行股票质押式回购交易的公告 截至公告披露日，亚宝投资及其一致行动人累计质押股份情况如下： | 已质押股份情 | 未质押股份情 | 占公 | 本次质押前 | 本次质押后 | 占其所 | 况 | 况 | 持股比 | 司总 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | -- ...

Core Viewpoint - The company plans to repurchase shares starting from May 16, 2025, with an estimated amount of 50 million to 100 million yuan aimed at reducing registered capital [1] Group 1 - As of October 31, the company has repurchased a total of 8 million shares, accounting for 1.14% of the total share capital [1] - The total amount paid for the repurchased shares is 52.1519 million yuan, with a repurchase price range of 6.30 yuan to 6.65 yuan per share [1] - The company will implement the repurchase at its discretion during the repurchase period and will disclose progress in a timely manner [1]